Novozymes is the world leader in bioinnovation, producing a wide range of industrial enzymes, microorganisms, and biopharmaceutical ingredients.
08 February 2016
Today, Novozymes announces the formation of three divisions: Household Care & Technical Industries, Agriculture & Bioenergy and Food & Beverages.
19 January 2016
Solid financial results in 2015; 2016 outlook of 8-10% growth in net profit despite expectations of a challenging year for sales growth
22 October 2015
9M sales and profit in line with August expectations; full-year outlook narrowed
06 August 2015
Full-year profit outlook maintained. Sales growth expectations revised
23 April 2015
Q1 in line with expectations; 2015 outlook adjusted for currencies
27 March 2015
Pursuant to company announcement no. 11, 2015, a reduction of the company’s B common stock by DKK 13,400,000 via cancellation of 6,700,000 treasury B stocks was adopted at the Annual Shareholders’ Meeting of Novozymes A/S on February 25, 2015.
25 February 2015
Today Novozymes A/S held its Annual Shareholders’ Meeting.
29 January 2015
On February 2, 2015, Novozymes will initiate a stock buyback program as announced in Company announcement No. 1 of January 20, 2015.
20 January 2015
Positive outlook for 2015. Long-term targets updated
23 October 2014
Increased expectations for full-year profit. 2014 sales growth on track
Visit archive to view all company announcements
Former Secretary General of NATO Anders Fogh Rasmussen and Novozymes’ CEO take steps to highlight Europe’s problematic addiction to oil – and what can be done about it
February 3 2016
The product Alterion is based on beneficial bacteria that improve feed utilization and provide a natural alternative to antibiotic growth promoters on poultry farms.
January 25 2016
The new stand-alone company Albumedix will continue to develop albumin-based products and technologies for the pharmaceutical industry.
January 19 2016
| Copyright © 2016 Novozymes. All Rights Reserved.